PL3395817T3 - Analog pirydo[1,2-a]pirymidonu, jego krystaliczna postać, jego związek pośredni i sposób jego wytwarzania - Google Patents

Analog pirydo[1,2-a]pirymidonu, jego krystaliczna postać, jego związek pośredni i sposób jego wytwarzania

Info

Publication number
PL3395817T3
PL3395817T3 PL16874904T PL16874904T PL3395817T3 PL 3395817 T3 PL3395817 T3 PL 3395817T3 PL 16874904 T PL16874904 T PL 16874904T PL 16874904 T PL16874904 T PL 16874904T PL 3395817 T3 PL3395817 T3 PL 3395817T3
Authority
PL
Poland
Prior art keywords
pyrido
preparation
crystal form
method therefor
pyrimidone
Prior art date
Application number
PL16874904T
Other languages
English (en)
Inventor
Tao Yu
Ning Li
Lingwei Kong
Peipei JIANG
Yong Wang
Zhemin RONG
Changjun WANG
Feng Guo
Zongbin LI
Zheng Wang
Jiahu WU
Chengde Wu
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. filed Critical Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Publication of PL3395817T3 publication Critical patent/PL3395817T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL16874904T 2015-12-16 2016-12-16 Analog pirydo[1,2-a]pirymidonu, jego krystaliczna postać, jego związek pośredni i sposób jego wytwarzania PL3395817T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510951482 2015-12-16
EP16874904.2A EP3395817B1 (en) 2015-12-16 2016-12-16 Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
PCT/CN2016/110284 WO2017101847A1 (zh) 2015-12-16 2016-12-16 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法

Publications (1)

Publication Number Publication Date
PL3395817T3 true PL3395817T3 (pl) 2022-05-02

Family

ID=59055711

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16874904T PL3395817T3 (pl) 2015-12-16 2016-12-16 Analog pirydo[1,2-a]pirymidonu, jego krystaliczna postać, jego związek pośredni i sposób jego wytwarzania

Country Status (14)

Country Link
US (1) US10479789B2 (pl)
EP (1) EP3395817B1 (pl)
JP (1) JP7037483B2 (pl)
KR (1) KR20180095565A (pl)
CN (1) CN108602815B (pl)
AU (1) AU2016369835B2 (pl)
CA (1) CA3008689A1 (pl)
DK (1) DK3395817T3 (pl)
ES (1) ES2908498T3 (pl)
HK (1) HK1256044A1 (pl)
PL (1) PL3395817T3 (pl)
RU (1) RU2753696C2 (pl)
WO (1) WO2017101847A1 (pl)
ZA (1) ZA201804007B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3971175A4 (en) * 2019-05-13 2022-11-09 Luoxin Healthcare Science and Technology Development (Beijing) Ltd. CRYSTAL FORM OF A QUINAZOLINONE COMPOUND AND PROCESS FOR THEIR PRODUCTION
EP4119557A4 (en) * 2020-03-10 2024-04-10 Chia Tai Tianqing Pharmaceutical Group Co Ltd PHARMACEUTICAL COMBINATION WITH A PYRIDINO[1,2-A PYRIMIDINONE COMPOUND
WO2022057812A1 (zh) * 2020-09-15 2022-03-24 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗外周T细胞淋巴瘤的用途
WO2022121929A1 (zh) * 2020-12-08 2022-06-16 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途
CN115671289B (zh) * 2021-07-27 2024-04-26 广州嘉越医药科技有限公司 药物组合及其应用
WO2023169488A1 (zh) * 2022-03-09 2023-09-14 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1699A (en) 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US20100311736A1 (en) 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
CN102206222B (zh) 2011-04-14 2013-04-10 中山大学 一种双脂肪氨基取代吲哚喹啉衍生物及其制备方法和制备抗肿瘤药物中的应用
CN103539777B (zh) 2012-07-13 2016-03-02 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) * 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use
CN103788071A (zh) 2012-11-01 2014-05-14 中国人民解放军第二军医大学 N-(5-(喹啉-6-基)吡啶-3-基)苯磺酰胺衍生物、制备方法及治疗用途
ES2754264T3 (es) 2014-06-17 2020-04-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd Análogo de piridin[1,2-a]pirimidona utilizado como inhibidor de PI3K
CN105461711B (zh) 2014-06-17 2018-11-06 正大天晴药业集团股份有限公司 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
JP6386177B2 (ja) 2014-06-17 2018-09-05 ツーセン ファーマシューティカル カンパニー リミテッド ｍＴＯＲ／ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミジノン類似体

Also Published As

Publication number Publication date
EP3395817A1 (en) 2018-10-31
US20180319799A1 (en) 2018-11-08
HK1256044A1 (zh) 2019-09-13
AU2016369835A1 (en) 2018-07-19
RU2753696C2 (ru) 2021-08-19
RU2018125475A (ru) 2020-01-16
JP7037483B2 (ja) 2022-03-16
JP2018537497A (ja) 2018-12-20
EP3395817B1 (en) 2022-02-23
CA3008689A1 (en) 2017-06-22
EP3395817A4 (en) 2019-08-07
ZA201804007B (en) 2019-05-29
WO2017101847A1 (zh) 2017-06-22
US10479789B2 (en) 2019-11-19
CN108602815B (zh) 2020-07-28
KR20180095565A (ko) 2018-08-27
AU2016369835B2 (en) 2020-10-15
CN108602815A (zh) 2018-09-28
DK3395817T3 (da) 2022-03-21
ES2908498T3 (es) 2022-04-29
RU2018125475A3 (pl) 2020-02-28

Similar Documents

Publication Publication Date Title
ZA201802976B (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
PL3453707T3 (pl) Pochodna benzazepiny, sposób wytwarzania, kompozycja farmaceutyczna i jej zastosowanie
HK1256044A1 (zh) 吡啶並[1，2-a]嘧啶酮類似物、其晶型、其中間體及其製備方法
EP3371187A4 (en) 2- (1H-INDAZOLE-3-YL) -3H-IMIDAZO [4,5-C] PYRIDINE AND ITS USE AS AN INHIBITOR OF INHIBITOR
IL255488B (en) Pyrido[4,3-di]pyrimidine derivative and its pharmaceutically acceptable salt
EP3138839A4 (en) Pyridone or pyrimidone derivative, preparation method therefor and application thereof
EP3546460A4 (en) PYRIMIDO [5,4-B] INDOLIZIN OR PYRIMIDO [5,4-B] PYRROLIZIN COMPOUND, PRODUCTION METHOD AND USE THEREOF
IL263511B (en) H1–pyrazolo[4, 3–b]pyridines as pde1 inhibitors
HK1225723A1 (zh) 取代的咪唑並[1，2-a]吡啶甲酰胺及其用途
ZA201900236B (en) Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof
EP3689871A4 (en) 1,2-DIHYDROPYRROL [3,4-C] PYRIDIN / PYRIMIDIN-3-ONE DERIVATIVE 4,6,7-TRISUBSTITUDE AND ITS USE
EP3150584A4 (en) 3,4-dihydroquinazoline derivative and complex preparation containing same
EP3227292A4 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
IL253427B (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose
EP3324971A4 (en) Zolpidem composition and process for preparing the same
AU2014904868A0 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
HK1206334A1 (en) Dehydrothiamine [2,3-c]quinoline-12-ketone derivatives, and preparation method and application thereof [2,3-c]-12-
IL235077A0 (en) New derivatives of thiochromano[2,3-c]quino lin-12-one, its preparation method and application
SG10201406318YA (en) Novel thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof